Indeed, the AFP immunization/anti-PD1 combination therapy delayed HCC progression, whereas the AFP immunization/anti–PD-L1 combination therapy strongly inhibited the development and progression of most HCC nodules (Supplemental Figure 25). Here, AFP is linked to hepatocellular carcinoma.